Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity

NCT00094146 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
160
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Novartis